Deepa Upadhyaya, MD
Cardiovascular Disease · Kansas City, MONPI 1891906012
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,570 of the $58,179 with a category attached, or 90.4%. E.r. Squibb & Sons, L.L.C. accounts for 99.7% of it on its own, with 1 other manufacturer making up the rest. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $1531.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$58K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$196
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$52,57090%
- Travel & lodging$4,0427%
- Food & beverage$1,2572%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 30 | $57,983 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $196 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$57,619
How this compares
$58,179 in reported general payments places this provider in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 147 | $191,880 |
| EliquisApixaban | 165 | $168,946 |
| EntrestoSacubitril/Valsartan | 95 | $103,358 |
| XareltoRivaroxaban | 45 | $56,314 |
| OzempicSemaglutide | 46 | $42,123 |
| MultaqDronedarone Hcl | 39 | $36,399 |
| Repatha SureclickEvolocumab | 48 | $35,882 |
| FarxigaDapagliflozin Propanediol | 19 | $22,629 |
| MounjaroTirzepatide | 13 | $13,307 |
| Valsartan | 108 | $2,831 |
| Metoprolol Succinate | 165 | $2,213 |
| Ezetimibe | 88 | $2,208 |
| Midodrine Hcl | 29 | $1,596 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $1,238 |
| Atorvastatin Calcium | 142 | $1,207 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Kansas City
- Mikhail KosiborodKansas City$1.1M
- John SpertusKansas City$360K
- Kyle LehenbauerKansas City$108K
- David SkolnickKansas City$44K
- Garth GrahamKansas City$32K
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- James FairlambColumbia$342K
- James EllisonChesterfield$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.